留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

《原发性肝癌诊疗指南(2022年版)》更新要点解读

金保 杜顺达 毛一雷 桑新亭

金保, 杜顺达, 毛一雷, 桑新亭. 《原发性肝癌诊疗指南(2022年版)》更新要点解读[J]. 协和医学杂志, 2022, 13(5): 789-795. doi: 10.12290/xhyxzz.2022-0274
引用本文: 金保, 杜顺达, 毛一雷, 桑新亭. 《原发性肝癌诊疗指南(2022年版)》更新要点解读[J]. 协和医学杂志, 2022, 13(5): 789-795. doi: 10.12290/xhyxzz.2022-0274
JIN Bao, DU Shunda, MAO Yilei, SANG Xinting. Interpretation on the Updated Points of Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 789-795. doi: 10.12290/xhyxzz.2022-0274
Citation: JIN Bao, DU Shunda, MAO Yilei, SANG Xinting. Interpretation on the Updated Points of Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 789-795. doi: 10.12290/xhyxzz.2022-0274

《原发性肝癌诊疗指南(2022年版)》更新要点解读

doi: 10.12290/xhyxzz.2022-0274
基金项目: 

国家自然科学基金 81972698

详细信息
    通讯作者:

    杜顺达, E-mail: dushd@pumch.cn

  • 中图分类号: R735.7

Interpretation on the Updated Points of Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

Funds: 

National Natural Science Foundation of China 81972698

More Information
  • 摘要: 自《原发性肝癌诊疗规范(2019年版)》发布以来,国内外在肝癌诊治领域涌现出许多新的循证医学高级别证据,尤其是多项符合中国肝癌患者诊疗的研究成果相继发表。为进一步规范我国肝癌诊疗行为,国家卫生健康委员会组织全国肝癌领域的多学科专家,更新并发布了《原发性肝癌诊疗指南(2022年版)》,旨在实现《“健康中国2030”规划纲要》提出的2030年总体癌症5年生存率提高15%的目标。本文将对2022年版指南的主要更新要点进行解读,以期推动新版指南的广泛传播与实施。
    作者贡献:金保负责查阅文献,撰写论文初稿;毛一雷和桑新亭负责修订论文;杜顺达负责指导论文撰写、修订论文。
    利益冲突:所有作者均声明不存在利益冲突
  • 表  1  2019年版规范[5]与2022年版指南[6]推荐的一线和二线系统抗肿瘤治疗方案

    类别 2019年版规范 2022年版指南
    一线治疗 索拉非尼
    仑伐替尼
    FOLFOX4化疗
    阿替利珠单抗+贝伐珠单抗
    信迪利单抗+贝伐珠单抗类似物
    多纳非尼
    仑伐替尼
    索拉非尼
    FOLFOX4化疗
    其他*
    二线治疗 瑞戈非尼
    其他#
    瑞戈非尼
    阿帕替尼
    卡瑞利珠单抗
    替雷利珠单抗
    其他#
    *免疫检查点抑制剂联合小分子抗血管生成药物的多项临床研究正在开展中,此类研究包括但不限于:卡瑞利珠单抗联合阿帕替尼Ⅲ期临床研究(SHR-1210-Ⅲ-310),仑伐替尼联合帕博利珠单抗Ⅲ期临床研究(LEAP 002),仑伐替尼联合纳武利尤单抗Ⅰb期临床研究(Study 117),CS1003(PD-1单抗)联合仑伐替尼Ⅲ期临床研究(CS1003-305),特瑞普利单抗联合仑伐替尼Ⅲ期临床研究等;此外,免疫检查点抑制剂与其他药物联合的临床研究也在开展中,如卡瑞利珠单抗联合奥沙利铂为主的系统化疗的Ⅲ期临床研究,度伐利尤单抗联合曲美木单抗Ⅲ期临床研究(HIMALAYA),信迪利单抗联合IBI310(抗CTLA-4单抗)Ⅲ期临床研究等; #如纳武利尤单抗、帕博利珠单抗、卡博替尼、雷莫芦单抗
    下载: 导出CSV
  • [1] Zheng RS, Zhang SW, Zeng HM, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2: 1-9. doi:  10.1016/j.jncc.2022.02.002
    [2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71: 209-249. doi:  10.3322/caac.21660
    [3] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J]. 临床肿瘤学杂志, 2011, 16: 929-946. doi:  10.3969/j.issn.1009-0460.2011.10.017
    [4] 中华人民共和国卫生和计划生育委员会. 原发性肝癌诊疗规范(2017年版)[J]. 中国实用外科杂志, 2017, 37: 705-720. doi:  10.19538/j.cjps.issn1005-2208.2017.07.01
    [5] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 中华消化外科杂志, 2020, 19: 1-20. doi:  10.3760/cma.j.issn.1673-9752.2020.01.001
    [6] 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗指南(2022年版)[J]. 中华消化外科杂志, 2022, 21: 143-168. doi:  10.3760/cma.j.cn115610-20220124-00053
    [7] 中共中央国务院. 《"健康中国2030"规划纲要》[EB/OL ]. (2016-10-25)[2022-05-01]. http://www.gov.cn/zhengce/2016-10/25/content_5124174.htm.
    [8] Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables[J]. J Clin Epidemiol, 2011, 64: 383-394. doi:  10.1016/j.jclinepi.2010.04.026
    [9] Balshem H, Helfand M, Schunemann HJ, et al. GRADE guidelines: 3. Rating the quality of evidence[J]. J Clin Epidemiol, 2011, 64: 401-406. doi:  10.1016/j.jclinepi.2010.07.015
    [10] Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength[J]. J Clin Epidemiol, 2013, 66: 726-735. doi:  10.1016/j.jclinepi.2013.02.003
    [11] Durieux N, Vandenput S, Pasleau F. OCEBM levels of evidence system[J]. Rev Med Liege, 2013, 68: 644-649.
    [12] Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma[J]. J Cancer Res Clin Oncol, 2004, 130: 417-422.
    [13] Fan R, Papatheodoridis G, Sun J, et al. aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis[J]. J Hepatol, 2020, 73: 1368-1378. doi:  10.1016/j.jhep.2020.07.025
    [14] Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers[J]. Cancer Epidemiol Biomarkers Prev, 2014, 23: 144-153. doi:  10.1158/1055-9965.EPI-13-0870
    [15] Best J, Bechmann LP, Sowa JP, et al. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis[J]. Clin Gastroenterol Hepatol, 2020, 18: 728-735. e4. doi:  10.1016/j.cgh.2019.11.012
    [16] Caviglia GP, Abate ML, Petrini E, et al. Highly sensitive alpha-fetoprotein, Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection[J]. Hepatol Res, 2016, 46: E130-E135. doi:  10.1111/hepr.12544
    [17] Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocel-lular Carcinoma and Prediction of Survival in Patients[J]. Clin Gastroenterol Hepatol, 2016, 14: 875-886. e6. doi:  10.1016/j.cgh.2015.12.042
    [18] Huang C, Fang M, Xiao X, et al. Validation of the GALAD model for early diagnosis and monitoring of hepatocellular carcinoma in Chinese multicenter study[J]. Liver Int, 2022, 42: 210-223. doi:  10.1111/liv.15082
    [19] Wang Y, Tian Y. miRNA for diagnosis and clinical implications of human hepatocellular carcinoma[J]. Hepatol Res, 2016, 46: 89-99. doi:  10.1111/hepr.12571
    [20] Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma[J]. J Clin Oncol, 2011, 29: 4781-4788. doi:  10.1200/JCO.2011.38.2697
    [21] Sheng X, Ji Y, Ren GP, et al. A standardized pathological proposal for evaluating microvascular invasion of hepatocellular carcinoma: a multicenter study by LCPGC[J]. Hepatol Int, 2020, 14: 1034-1047. doi:  10.1007/s12072-020-10111-4
    [22] Zhang X, Li J, Shen F, et al. Significance of presence of microvascular invasion in specimens obtained after surgical treatment of hepatocellular carcinoma[J]. J Gastroenterol Hepatol, 2018, 33: 347-354. doi:  10.1111/jgh.13843
    [23] Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study[J]. Liver Int, 2015, 35: 2155-2166. doi:  10.1111/liv.12818
    [24] 中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中华消化外科杂志, 2021, 20: 600-616. doi:  10.3760/cma.j.cn115610-20210512-00223
    [25] Kaseb AO, Hasanov E, Cao HST, et al. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial[J]. Lancet Gastroenterol Hepatol, 2022, 7: 208-218. doi:  10.1016/S2468-1253(21)00427-1
    [26] Shi HY, Wang SN, Wang SC, et al. Preoperative transarterial chemoembolization and resection for hepatocellular carcinoma: a nationwide Taiwan database analysis of long-term outcome predictors[J]. J Surg Oncol, 2014, 109: 487-493. doi:  10.1002/jso.23521
    [27] Zhou WP, Lai EC, Li AJ, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma[J]. Ann Surg, 2009, 249: 195-202. doi:  10.1097/SLA.0b013e3181961c16
    [28] Singal AG, Lim JK, Kanwal F. AGA Clinical Practice Update on Interaction Between Oral Direct-Acting Antivirals for Chronic Hepatitis C Infection and Hepatocellular Carcinoma: Expert Review[J]. Gastroenterology, 2019, 156: 2149-2157. doi:  10.1053/j.gastro.2019.02.046
    [29] Sapena V, Enea M, Torres F, et al. Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis[J]. Gut, 2022, 71: 593-604. doi:  10.1136/gutjnl-2020-323663
    [30] Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis[J]. Hepatology, 2018, 67: 381-400. doi:  10.1002/hep.29485
    [31] Lee S, Kim KW, Song GW, et al. The Real Impact of Bridging or Downstaging on Survival Outcomes after Liver Transplantation for Hepatocellular Carcinoma[J]. Liver Cancer, 2020, 9: 721-733. doi:  10.1159/000507887
    [32] Mazzaferro V, Citterio D, Bhoori S, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial[J]. Lancet Oncol, 2020, 21: 947-956. doi:  10.1016/S1470-2045(20)30224-2
    [33] Mehta N, Guy J, Frenette CT, et al. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study[J]. Clin Gastroenterol Hepatol, 2018, 16: 955-964. doi:  10.1016/j.cgh.2017.11.037
    [34] Nordness MF, Hamel S, Godfrey CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2020, 20: 879-883. doi:  10.1111/ajt.15617
    [35] Gao Q, Anwar IJ, Abraham N, et al. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors[J]. Cancers (Basel), 2021, 13: 6307. doi:  10.3390/cancers13246307
    [36] Qu S, Worlikar T, Felsted AE, et al. Non-thermal histotripsy tumor ablation promotes abscopal immune responses that enhance cancer immunotherapy[J]. J Immunother Cancer, 2020, 8: e000200. doi:  10.1136/jitc-2019-000200
    [37] Greten TF, Mauda-Havakuk M, Heinrich B, et al. Combined locoregional-immunotherapy for liver cancer[J]. J Hepatol, 2019, 70: 999-1007. doi:  10.1016/j.jhep.2019.01.027
    [38] Mizukoshi E, Yamashita T, Arai K, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma[J]. Hepatology, 2013, 57: 1448-1457. doi:  10.1002/hep.26153
    [39] Slovak R, Ludwig JM, Gettinger SN, et al. Immuno-thermal ablations-boosting the anticancer immune response[J]. J Immunother Cancer, 2017, 5: 78. doi:  10.1186/s40425-017-0284-8
  • 加载中
表(1)
计量
  • 文章访问数:  181
  • HTML全文浏览量:  15
  • PDF下载量:  132
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-13
  • 录用日期:  2022-05-27
  • 网络出版日期:  2022-06-22
  • 刊出日期:  2022-09-30

目录

    /

    返回文章
    返回

    【通知】尊敬的读者、作者及编者:因特殊原因,本站自2022.9.30至10.24日期间实施6—24点开放,其他时段访问受限,给您带来不便敬请谅解!10.25日恢复如常。